MASP2 and IgA glomerulonephritis: MASP-2 contributes to IgA nephropathy, and an antibody against MASP-2 to treat IgA nephropathy (OMS721, Omeros, Seattle, WA, USA) is currently under investigation, where the phase-2 trial showed reduced proteinuria in IgA nephropathy by 50–90% and stabilized or increased glomerular filtration rates when treating with the antibody (Clinical Trial ID: NCT02682407)46.